Arvinas develops and commercializes small molecular therapeutics for the treatment of pro-inflammatory and autoimmune diseases.Read more
Arvinas's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 28M. Over the last four quarters, Arvinas's revenue has decreased by 27%. Specifically, in Q2 2021's revenue was $5.5M; in Q1 2021, it was $5.5M; in Q4 2020, it was $2.2M; in Q3 2020, Arvinas's revenue was $7.6M.